← Leaderboards
Thomas Stinchcombe
Univ Of North Carolina Chapel Hill
$895,675
Attributed
$895,675
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $482.6K · FY2006–25$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$895,675 · 7
By mechanism
P30$766,537 · 2
M01$129,138 · 5
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Ethan M. Basch$11,364,971
- Henry Shelton Earp$37,241,767
- Bryce B Reeve$11,567,326
- Daniel S. Reuland$5,923,387
- Mina C Hosseinipour$32,208,429
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantInstitutionResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabaseResourcesClinical TrialsFundingPurposeDoseSourceUnited States National Institutes Of HealthDesignSolid NeoplasmAbraxaneStandards Of Weights And MeasuresCarboplatinGemcitabineCancer PatientEnrollmentEnsureInfrastructureClinical InvestigatorCancer Center Support GrantClinical Data
Grant awards (7)
Clinical Protocol & Data Management (CPDM)$482,551
P30 · FY2025 · CA · contact PI
Clinical Protocol and Data Management$283,986
P30 · FY2021 · CA · contact PI
CLINICAL TRIAL: PHASE I TRIAL OF ABRAXANE IN COMBINATION WITH GEMCITABINE IN SOL$5,050
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: CISPLATIN/ETOPOSIDE OR CARBOPLATIN/PEMETREXED IN PATIENTS WITH S$1,683
M01 · FY2008 · RR · contact PI
LCCC 0412: PHASE I CARBOPLATIN AND ABRAXANE IN PATIENTS WITH SOLID TUMORS$14,256
M01 · FY2007 · RR · contact PI
PHASE I TRIAL OF ABRAXANE IN COMBINATION WITH GEMCITABINE IN SOLID TUMORS$12,005
M01 · FY2007 · RR · contact PI
LCCC 0412: PHASE I CARBOPLATIN AND ABRAXANE IN PATIENTS WITH SOLID TUMORS$96,144
M01 · FY2006 · RR · contact PI